CN1901918A - 3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途 - Google Patents

3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途 Download PDF

Info

Publication number
CN1901918A
CN1901918A CNA2004800394544A CN200480039454A CN1901918A CN 1901918 A CN1901918 A CN 1901918A CN A2004800394544 A CNA2004800394544 A CN A2004800394544A CN 200480039454 A CN200480039454 A CN 200480039454A CN 1901918 A CN1901918 A CN 1901918A
Authority
CN
China
Prior art keywords
aza
dibenzo
azulene
oxa
thia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800394544A
Other languages
English (en)
Chinese (zh)
Inventor
M·梅尔切普
M·梅希奇
D·佩希奇
I·扎波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutika dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutika dd filed Critical Pliva Farmaceutika dd
Publication of CN1901918A publication Critical patent/CN1901918A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2004800394544A 2003-11-21 2004-11-19 3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途 Pending CN1901918A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP20030959A 2003-11-21
HR20030959A HRP20030959A2 (enExample) 2003-11-21 2003-11-21

Publications (1)

Publication Number Publication Date
CN1901918A true CN1901918A (zh) 2007-01-24

Family

ID=34611163

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800394544A Pending CN1901918A (zh) 2003-11-21 2004-11-19 3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途

Country Status (10)

Country Link
US (1) US20070111990A1 (enExample)
EP (1) EP1684766B1 (enExample)
JP (1) JP2007512308A (enExample)
CN (1) CN1901918A (enExample)
AT (1) ATE365556T1 (enExample)
CA (1) CA2546591A1 (enExample)
DE (1) DE602004007289T2 (enExample)
ES (1) ES2289573T3 (enExample)
HR (1) HRP20030959A2 (enExample)
WO (1) WO2005049036A1 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711489A (en) * 1971-03-31 1973-01-16 Pfizer Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4198421A (en) * 1978-11-30 1980-04-15 E. I. Du Pont De Nemours And Company Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
ATE178893T1 (de) * 1990-01-11 1999-04-15 Upjohn Co 6,7,8,9-tetrahydro-3h-benz(e)indolheterocyclen mit wirkung auf das zentrale nervensystem
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
HRP20020304B1 (en) * 2002-04-10 2008-04-30 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof

Also Published As

Publication number Publication date
HRP20030959A2 (enExample) 2005-10-31
JP2007512308A (ja) 2007-05-17
ES2289573T3 (es) 2008-02-01
DE602004007289D1 (de) 2007-08-09
EP1684766A1 (en) 2006-08-02
US20070111990A1 (en) 2007-05-17
WO2005049036A1 (en) 2005-06-02
HK1098670A1 (en) 2007-07-27
ATE365556T1 (de) 2007-07-15
EP1684766B1 (en) 2007-06-27
CA2546591A1 (en) 2005-06-02
DE602004007289T2 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
CN1222288C (zh) 3－取代的羟吲哚衍生物作为kcnq钾通道调节剂的用途
CN1630636A (zh) 二氢吲哚衍生物及其作为5－ht2受体配体的用途
CN1450998A (zh) 含铜的胺氧化酶的抑制剂
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1823062A (zh) 作为5－羟色胺－6配体的磺酰基二氢苯并咪唑酮化合物
CN1780626A (zh) 双相性精神障碍和相关症状的治疗
CN1225584A (zh) 四氢β咔啉化合物
CN1886130A (zh) 2－硫杂－二苯并[e,h]薁在制备治疗和预防中枢神经系统疾病和障碍的药物制剂中的应用
CN1678302A (zh) 取代的5－苯并二氢吡喃－5－基－乙胺化合物及其在治疗青光眼中的用途
CN1901918A (zh) 3－氮杂－1－氧杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
CN1902206A (zh) 1－氮杂－2－氧杂－二苯并[e,h]薁的制备以及它们用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
CN1901904A (zh) 1,2－二氮杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
CN1662242A (zh) 用于治疗与神经营养蛋白相关和疾病的药物组合物
CN1897938A (zh) 1，3－二氮杂－二苯并[e,h]薁用于制备治疗和预防中枢神经系统疾病和障碍的药物制剂的用途
CN1938016A (zh) 苯并萘并薁在制备用于治疗和预防中枢神经系统疾病和病症的药物制剂中的用途
EP1684742B1 (en) Use of 1-oxadibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
JP2007512309A (ja) 中枢神経系の疾患及び障害の治療及び予防用医薬製剤を製造するための１−チア−３−アザ−ジベンゾ［ｅ，ｈ］アズレン類の使用
JP2007512305A (ja) 中枢神経系の疾患及び障害の治療及び予防用医薬製剤を製造するための１−アザ−ジベンゾ［ｅ，ｈ］アズレン類の使用
HK1098670B (en) Use of 3-aza-1-oxa-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system disease and disorders
CN1886366A (zh) 环戊基衍生物
HK1098668B (en) Use of 1,3-diaza-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
HK1098694A (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
HK1102557A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
HK1040395A (en) 5ht1 antagonists for antidepressant therapy
HK1058794A (en) Inhibitors of copper-containing amine oxidases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication